Study guide
8.4 Bronchodilator Response Studies
NBRC Registered Pulmonary Function Technologist RPFT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Content Outline Domains & Study Plan
2 Spirometry Instrumentation
2.1 Spirometer Types, Setup & Maintenance 2.2 Spirometer Calibration & Linearity 2.3 Spirometer Troubleshooting
3 Blood Gas & Gas Analyzers
3.1 Blood Gas Analyzer Setup, Maintain, Calibrate 3.2 Gas Analyzers & Water/Gas Absorbers 3.3 ABG & Gas Analyzer Troubleshooting and QC
4 Body Box, Exercise & Monitoring Equipment
4.1 Body Plethysmograph Setup & Calibration 4.2 Exercise, Field Walking & ECG Equipment 4.3 Pressure Devices, Valves & Gas Delivery Systems
5 Ancillary Equipment & Infection Control
5.1 Body Habitus, Sampling & Aerosol Equipment 5.2 Monitors & Emergency Management Equipment 5.3 Infection Control Materials & Methods
6 Quality Control Systems
6.1 Mechanical QC Devices 6.2 Biological Controls & Proficiency Testing 6.3 Laboratory Quality Management & SOPs
7 Patient Preparation & Safety
7.1 Body Habitus Measurements & Estimates 7.2 Patient Safety, Precautions & Adverse Events
8 Spirometry Procedures
8.1 Selecting Spirometry Protocols & Equipment 8.2 Performing Standard & Position-Variant Spirometry 8.3 Evaluating Spirometry Acceptability & Repeatability 8.4 Bronchodilator Response Studies
9 Static Lung Volumes
9.1 Gas Dilution Lung Volume Methods 9.2 Body Plethysmography Lung Volumes 9.3 Evaluating Lung Volume Validity
10 Diffusing Capacity (DLCO)
10.1 DLCO Protocol & Equipment Selection 10.2 Performing the DLCO Maneuver 10.3 Evaluating DLCO Validity
11 Blood Gas Sampling & Analysis Procedures
11.1 Arterial & Capillary Blood Sample Collection 11.2 Performing Blood Gas Analysis 11.3 CO-oximetry / Hemoximetry Procedures
12 Airway Responsiveness, Resistance & Muscle Strength
12.1 Bronchial Provocation Studies 12.2 Airways Resistance & Conductance by Plethysmography 12.3 Respiratory Muscle Strength (MIP/MEP/CPF)
13 Exercise, Oxygen, Home Testing & Education
13.1 Field Walking Tests (6MWT, Shuttle) 13.2 Monitored Exercise Testing 13.3 Oxygen Assessment & Titration 13.4 Home Testing Instruction & Patient Education
14 Calculations & Reference Ranges
14.1 Spirometry Calculations & Reference Equations 14.2 Lung Volume & DLCO Calculations/Corrections 14.3 Blood Gas & CO-oximetry Derived Calculations 14.4 Exercise, Oximetry & Special Test Calculations
15 Evaluating Result Reliability
15.1 Spirometry & Lung Volume Reliability 15.2 DLCO & Exercise Test Reliability 15.3 ABG, Monitoring & QC Reliability
16 Clinical Implications & Reporting
16.1 Pattern Recognition: Obstruction, Restriction, Mixed, Severity 16.2 Clinical Implications: DLCO, ABG, Airway Response, Exercise & Lab Context
8.4 Bronchodilator Response Studies
Key Takeaways Explain This Topic AI
Bronchodilator response studies combine NBRC II.A.15.a (select), II.B.15.a (perform), and II.C.15.a (evaluate validity), plus inhaled medication delivery tasks II.A.3/B.3
Protocol includes valid pre-drug spirometry, correct agent/device, appropriate wait after SABA (commonly about 10–15 minutes), and valid post-drug efforts using the same acceptability rules
Classic significance criteria are ≥12% and ≥200 mL improvement in FEV1 and/or FVC; ERS/ATS 2022 interpretive strategy emphasizes change >10% of the predicted value—NBRC candidates should know both frameworks
Withholding short- and long-acting bronchodilators before a true baseline follows lab SOP and visit purpose; document last doses when withholding is incomplete
MDI with spacer/valved holding chamber versus nebulizer selection affects deposition consistency; poor inhaler technique invalidates the 'post' comparison even if spirometry curves look acceptable
Last updated: August 2026
Where bronchodilator studies sit on the RPFT outline
Bronchodilator (BD) response testing is explicitly mapped on the NBRC PFT Detailed Content Outline to II.A.15.a (select), II.B.15.a (perform), and II.C.15.a (evaluate validity of results), with overlapping competence in inhaled medication delivery ( II.A.3 / II.B.3 ). On the exam, a single vignette may test whether you withheld meds correctly, chose MDI vs nebulizer, waited long enough, obtained acceptable post curves, and applied the right significance rule.
This section ties together protocol selection (8.1), maneuver performance (8.2), and acceptability/repeatability (8.3) into one pre/post workflow.
Purpose of the study
A bronchodilator response study asks whether airflow (and sometimes volume) improves meaningfully after an inhaled bronchodilator—classically a short-acting β2-agonist (SABA) such as albuterol. Results support asthma vs COPD discussions, guide therapy, and satisfy pretest pathways (e.g., before bronchial provocation in some algorithms). Your job is valid measurement and correct procedure , not final clinical diagnosis.
Pre/post protocol overview
Verify order and contraindications (unstable cardiac disease, allergy to agent, inability to perform spirometry, etc.).
Confirm medication washout appropriate to a true baseline when response is the question.
Perform pre-bronchodilator spirometry meeting acceptability/repeatability goals when possible.
Select and deliver the bronchodilator with correct device technique (II.A.3/B.3).
Wait the protocol interval (SABA peak effect window).
Perform post-bronchodilator spirometry with the same coaching standards.
Calculate change , apply significance criteria, and validate that both drug delivery and spirometry quality support the numbers (II.C.15.a).
Withholding medications (selection + performance logistics)
Why withhold?
If the patient arrives fully bronchodilated on LABA/LAMA/SABA, the “pre” FEV1 is already treated. You may still measure values on therapy , but you cannot claim a full acute response study from an unmedicated baseline.
Typical washout concepts taught in PFT practice
Exact lab SOPs vary; know the direction and order of magnitude for exams:
- Drug class Common withholding window before baseline BD study
- SABA (albuterol, etc.) About 4–6 hours
- SAMA (ipratropium) About 12 hours
- LABA / LAMA / many combos Often ~24 hours (some ultra-long agents longer per policy)
- Oral theophylline / other systemic agents Per medical director (often longer)
- Inhaled corticosteroids Usually continued (not acute bronchodilators); document
Visit-purpose exception: Monitoring “usual control” may allow continued maintenance therapy— document last doses and what the order intended.
Check-in action: If washout was violated, contact the ordering pathway; options include reschedule, proceed as on-therapy spirometry without calling it a clean BD response, or proceed with documented limitation.
- Selecting the agent and delivery device (II.A.15.a + II.A.3)
- Agent
Most common: albuterol (salbutamol) via MDI or nebulizer; dose per lab protocol (e.g., multi-actuation MDI with spacer or unit-dose nebulization).
Alternatives (levalbuterol, addition of anticholinergic) only if ordered/protocolized.
Know allergies and cardiac precautions; hold for medical direction when red flags appear.
MDI (± spacer / valved holding chamber) vs nebulizer
Mode Selection advantages Failure modes that kill validity
MDI + spacer/VHC Fast, reproducible when technique is coached; common lab standard Actuating without inhale, poor seal on spacer, wrong timing, empty canister
MDI alone Available when spacer missing High oropharyngeal loss; coordination errors
Nebulizer Useful if patient cannot use MDI; tidal breathing delivery Wrong fill volume, insufficient nebulization time, leak at mouthpiece/mask, diluted dose
Performance of delivery (II.B.3): Teach slow deep inhalation with MDI+spacer, breath-hold as tolerated, multiple actuations separated per protocol, or quiet tidal breathing through nebulizer until sputter/time complete. If the patient chatters through a mask nebulizer with large facial leak, the post spirometry may be excellent quality while the drug dose was inadequate—II.C.15.a should catch that logical failure.
Wait times after SABA
SABA onset is rapid; labs typically wait about 10–15 minutes after the last actuation or after nebulization completion before post-testing (some protocols specify up to ~15–20 minutes). Waiting only 1–2 minutes under-samples peak effect. Waiting an hour without reason delays care and may add fatigue confounders.
Exam trap: Starting post efforts immediately after the first MDI puff “to save time” is a protocol error.
Performing pre and post spirometry (II.B.15.a)
Use the same device, filter type, posture, and coaching pre and post.
Pre set: pursue acceptable, repeatable efforts (8.3).
During the wait: patient rests; no unscheduled extra bronchodilator; monitor for tremor, tachycardia, or rare adverse effects.
Post set: full re-coaching—do not accept one weak post blow because “we already know they try hard.”
Special populations: children may need repeated demonstration after the wait; elderly may need longer recovery between post efforts.
Evaluating validity of the BD study (II.C.15.a)
A numerically large percent change is meaningless if:
Pre efforts were unacceptable (cough in first second, huge BEV, early termination misreported as FVC).
Post efforts are fewer/weaker solely due to fatigue or poor coaching.
Drug was not actually inhaled.
Wrong wait time or extra SABA between sets confused timing.
Different posture pre vs post (upright pre, slumped post) fabricated “response.”
Validity checklist for BD sessions:
- Check Pass looks like
- Pre quality Acceptable FEV1/FVC with stated repeatability or graded limitation documented
- Delivery Observed correct MDI/neb technique; full protocol dose
- Wait Protocol interval completed
- Post quality Acceptable efforts; not systematically worse coaching
- Calculation inputs Same index definitions; BTPS handled consistently
- Adverse events Documented; session stopped if unsafe
- Significant response: classic vs current interpretive strategy
NBRC candidates should know both the long-taught numeric rule and the ERS/ATS 2022 interpretive strategy approach used in modern reporting discussions.
Classic criterion (still widely taught and seen in many stems)
A significant bronchodilator response is often defined as an increase in FEV1 and/or FVC of:
- ≥12% of the baseline value and
- ≥200 mL (0.200 L) absolute improvement
Both percent and absolute thresholds are required in this classic rule— 12% alone of a very small FEV1 might not meet 200 mL; 200 mL alone on a large lung might not meet 12%.
Worked example (classic):
- Pre FEV1 = 2.00 L → post FEV1 = 2.30 L
- Absolute change = 0.30 L (≥0.20 L)
- Percent change = 0.30/2.00 = 15% (≥12%)
- → Significant by classic FEV1 criteria
Counterexample:
- Pre FEV1 = 1.00 L → post = 1.15 L
- Absolute = 0.15 L ( fails 200 mL) even though percent = 15%
- → Not significant by classic dual rule
- ERS/ATS 2022 approach (>10% predicted)
The 2022 ERS/ATS technical standard on interpretive strategies for routine lung function tests moved bronchodilator responsiveness toward expressing change relative to the predicted value , with a threshold of >10% of predicted for FEV1 or FVC as a preferred way to define a positive response (reducing bias when baseline is very low or high). Software and labs may report both classic baseline-percent/absolute rules and percent-predicted change.
Exam stance for ExamFinch / RPFT study:
Be able to calculate and recognize the classic ≥12% and ≥200 mL rule.
Know that current ATS/ERS interpretive strategy favors >10% of predicted as the modern significance framework.
Read the stem: if it cites “traditional” or gives only baseline values, apply classic math; if it cites 2022 strategy or predicted values, apply >10% predicted reasoning.
Do not invent hybrid rules (e.g., “12% of predicted and 200 mL”) unless a stem specifies a lab’s exact policy.
Which index improved?
Response may appear in FEV1 , FVC , or both. Isolated FVC improvement can occur in some obstruction/air-trapping patterns. Report which index met criteria and whether quality supports it.
Calculating percent change (classic) Percent change = Post − Pre Pre × 100 \text{Percent change} = \frac{\text{Post} - \text{Pre}}{\text{Pre}} \times 100 Percent change = Pre Post − Pre × 100
Use the reported best acceptable pre and post values for each index, not random mid-trials.
For percent predicted change (2022-style concept): Change % predicted = Post − Pre Predicted × 100 \text{Change \% predicted} = \frac{\text{Post} - \text{Pre}}{\text{Predicted}} \times 100 Change % predicted = Predicted Post − Pre × 100
Compare that result to the >10% threshold when using the 2022 approach.
Putting selection, performance, and validity together
Phase Domain tag Failure example
Choose BD protocol + washout + device II.A.15.a / II.A.3 Nebulizing saline “placebo” by mistake; no washout when response ordered
Deliver drug + wait + post FVC coaching II.B.15.a / II.B.3 Immediate post test at 60 seconds; one uncoached post blow
Judge quality + significance II.C.15.a Calling +18% significant when post FEV1 from coughed effort; ignoring 200 mL rule in classic stem
RPFT scenarios
Scenario 1: Pre FEV1 1.50 L (predicted 3.00 L), post 1.80 L. Classic: Δ=0.30 L (20%) → significant. 2022-style: 0.30/3.00 = 10% predicted → borderline/threshold depending on strict “>10%” wording—know both calculations.
Scenario 2: Patient uses MDI without spacer, actuates while talking; post FEV1 unchanged. Validity conclusion: possible failed delivery , not proof of irreversible obstruction—reteach and consider repeat administration per protocol.
Scenario 3: Pre efforts not repeatable (FEV1 scatter 0.35 L); post looks great. Do not over-interpret percent change until pre quality is addressed or limitations are boldly reported.
Safety and documentation
Record agent, dose, device, time of administration, wait time, and vital-sign/tolerance notes when required by SOP.
Document pre/post quality grades and any washout violations.
Manage side effects (tremor, tachycardia, nervousness); escalate rare bronchospasm or chest pain per emergency procedures (Chapter 7).
- Numbers and rules to memorize
- SABA withhold ~ 4–6 h ; LABA/LAMA often ~ 24 h (SOP-driven)
- Post-SABA wait ~ 10–15 min
- Classic response: ≥12% and ≥200 mL (FEV1 and/or FVC)
- ERS/ATS 2022 : responsiveness >10% of predicted
- Same acceptability rules pre and post; validate delivery not only curves
- Outline map: II.A/B/C.15.a + inhaled meds II.A.3/B.3
Master the workflow end-to-end, and bronchodilator items become structured rather than memorized trivia.